Cargando…

Comparison of molecular subtype distribution in triple-negative inflammatory and non-inflammatory breast cancers

INTRODUCTION: Because of its high rate of metastasis, inflammatory breast cancer (IBC) has a poor prognosis compared with non-inflammatory types of breast cancer (non-IBC). In a recent study, Lehmann and colleagues identified seven subtypes of triple-negative breast cancer (TNBC). We hypothesized th...

Descripción completa

Detalles Bibliográficos
Autores principales: Masuda, Hiroko, Baggerly, Keith A, Wang, Ying, Iwamoto, Takayuki, Brewer, Takae, Pusztai, Lajos, Kai, Kazuharu, Kogawa, Takahiro, Finetti, Pascal, Birnbaum, Daniel, Dirix, Luc, Woodward, Wendy A, Reuben, James M, Krishnamurthy, Savitri, Symmans, W Fraser, Van Laere, Steven J, Bertucci, François, Hortobagyi, Gabriel N, Ueno, Naoto T
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3978878/
https://www.ncbi.nlm.nih.gov/pubmed/24274653
http://dx.doi.org/10.1186/bcr3579
Descripción
Sumario:INTRODUCTION: Because of its high rate of metastasis, inflammatory breast cancer (IBC) has a poor prognosis compared with non-inflammatory types of breast cancer (non-IBC). In a recent study, Lehmann and colleagues identified seven subtypes of triple-negative breast cancer (TNBC). We hypothesized that the distribution of TNBC subtypes differs between TN-IBC and TN-non-IBC. We determined the subtypes and compared clinical outcomes by subtype in TN-IBC and TN-non-IBC patients. METHODS: We determined TNBC subtypes in a TNBC cohort from the World IBC Consortium for which IBC status was known (39 cases of TN-IBC; 49 cases of TN-non-IBC). We then determined the associations between TNBC subtypes and IBC status and compared clinical outcomes between TNBC subtypes. RESULTS: We found the seven subtypes exist in both TN-IBC and TN-non-IBC. We found no association between TNBC subtype and IBC status (P = 0.47). TNBC subtype did not predict recurrence-free survival. IBC status was not a significant predictor of recurrence-free or overall survival in the TNBC cohort. CONCLUSIONS: Our data show that, like TN-non-IBC, TN-IBC is a heterogeneous disease. Although clinical characteristics differ significantly between IBC and non-IBC, no unique IBC-specific TNBC subtypes were identified by mRNA gene-expression profiles of the tumor. Studies are needed to identify the subtle molecular or microenvironmental differences that contribute to the differing clinical behaviors between TN-IBC and TN-non-IBC.